6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2021

Commission File No. 001-39530

ImmunoPrecise Antibodies Ltd.

(Translation of registrant’s name into English)

3204-4464 Markham Street Victoria, British Columbian V8Z 7X8

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☐             Form 40-F  ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):  ☐

EXHIBIT INDEX

Exhibit	Description
99.1	Notice of Change of Auditor dated October 13, 2021
99.2	Letter from Crowe MacKay LLP as Former Auditor dated October 22, 2021
99.3	Letter from Grant Thornton LLP as Successor Auditor dated October 20, 2021

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

	IMMUNOPRECISE ANTIBODIES LTD.
Date: October 29, 2021
	By:	/s/ Lisa Helbling
	Name:	Lisa Helbling
	Title:	Chief Financial Officer

2

EX-99.1

Exhibit 99.1

NOTICE OF CHANGE OF AUDITOR

TO:	Grant Thornton LLP
	Crowe MacKay LLP
AND TO:	British Columbia Securities Commission
	Alberta Securities Commission
	Financial and Consumer Affairs Authority of Saskatchewan
	The Manitoba Securities Commission
	Ontario Securities Commission
	New Brunswick Financial and Consumer Services Commission
	Nova Scotia Securities Commission
	Prince Edward Island Office of the Superintendent of Securities
	Superintendent of Securities (Newfoundland and Labrador)

Notice is hereby given pursuant to Section 4.11 of National Instrument 51-102 – Continuous Disclosure Obligations (NI 51-102) of a proposed change of auditor of ImmunoPrecise Antibodies Ltd. (the Corporation).

1. Following the completion of a tender process for external auditor services, the board of directors of the Corporation determined to request the resignation of Crowe MacKay LLP (the Former Auditor) as its auditor effective as of November 1, 2021 and to appoint Grant Thornton LLP (the Successor Auditor) as the Corporation’s auditor effective as of November 1, 2021.

2. The auditor’s reports of the Former Auditor on the annual financial statements of the Corporation for the fiscal years ended April 30, 2021 and 2020 did not contain any modifications as to departures from generally accepted accounting principles or limitations in the scope of the audits.

3. In connection with the audits for the years ended April 30, 2021 and 2020 and through to the date hereof, there have been no reportable events, as defined in NI 51-102.

4. The Corporation has requested that the Former Auditor and the Successor Auditor each furnish a letter addressed to the securities regulators in each province in which the Corporation is a reporting issuer stating whether or not they agree with the information contained in this notice. A copy of each such letter to the securities administrators will be filed with this notice.

DATED as of the 13^th day of October, 2021.

IMMUNOPRECISE ANTIBODIES LTD.
Per:	(signed) “Lisa Helbling”
	Name: Lisa Helbling
	Title: Chief Financial Officer

1

EX-99.2

Exhibit 99.2

Crowe MacKay LLP   1100 - 1177 West Hastings St. Vancouver, BC V6E 4T5 Main  +1 (604) 687-4511 Fax     +1 (604) 687-5805   www.crowemackay.ca

October 22, 2021

British Columbia Securities Commission

Alberta Securities Commission

Financial and Consumer Affairs Authority of Saskatchewan

The Manitoba Securities Commission

Ontario Securities Commission

New Brunswick Financial and Consumer Services Commission

Nova Scotia Securities Commission

Prince Edward Island Office of the Superintendent of Securities

Superintendent of Securities (Newfoundland and Labrador)

Dear Sirs and Mesdames:

Re: ImmunoPrecise Antibodies Ltd. (the “Company”) – Change of Auditor

In accordance with Section 4.11 of National Instrument 51-102 - Continuous Disclosure Obligations, we have reviewed the information contained in the Company’s Notice of Change of Auditor dated October 13, 2021, (the “Notice”) and agree with the information contained therein, based upon our knowledge of the information relating to the said Notice and of the Company at this time.

We understand that the Notice, along with this letter and a similar letter from Grant Thornton LLP, will be provided to the Company’s registered shareholders with the meeting materials relating to the Company’s next Annual General Meeting of Shareholders.

Yours truly,

/s/ “Crowe MacKay LLP”

Crowe MacKay LLP

Chartered Professional Accountants

EX-99.3

Exhibit 99.3

GRANT THORNTON LLP	October 20, 2021
200 S. Sixth St.
Suite 1400
Minneapolis, MN 55402
D +1 612 332 0001	British Columbia Securities Commission
	Alberta Securities Commission
	Financial and Consumer Affairs Authority of Saskatchewan
	The Manitoba Securities Commission
	Ontario Securities Commission
	New Brunswick Financial and Consumer Services Commission
	Nova Scotia Securities Commission
	Prince Edward Island Office of the Superintendent of Securities
	Superintendent of Securities (Newfoundland and Labrador)
	RE: ImmunoPrecise Antibodies Ltd. (the “Corporation”)
	We have read the notice of change of auditor (the “Notice”) of the Corporation dated October 13, 2021 and are in agreement with the statements in such Notice as it relates to Grant Thornton LLP.
	Very truly yours,